Article

AcuFocus introduces new surgical planning device

AcuFocus has launched a new diagnostic and surgical planning instrument designed to further optimize clinical outcomes for its corneal inlay (Kamra) and streamline the patient care process.

 

Irvine, CA-AcuFocus has launched a new diagnostic and surgical planning instrument designed to further optimize clinical outcomes for its corneal inlay (Kamra) and streamline the patient care process.

AcuFocus developed the device, AcuTarget HD, in collaboration with Visiometrics.

“By combining our science with AcuFocus’ inlay centration expertise, I believe we have jointly developed a technology that will simplify and streamline the inlay patient selection and care process,” said Jan Bonel, chief executive officer of Visiometrics.

The new device offers a broader range of functionality than its predecessor by combining five diagnostic tools into one state-of-the-art instrument to provide practices with new objective data to support patient selection, inlay centration, and postoperative management.

“We understood that by having more objective information, practitioners are able to make better, more informed decisions,” said Jim Mazzo, chief executive officer and executive chairman of AcuFocus. “Not only does the (device) provide a broader range of objective patient information, it does so quickly and reliably. We believe this advanced device will become an invaluable addition to a surgeon’s practice.”

The new device will be on display for the first time in the AcuFocus booth (#E01) at the 2013 European Society of Cataract and Refractive Surgeons in Amsterdam on Oct. 5 through 9.

 

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
© 2024 MJH Life Sciences

All rights reserved.